Cogent Biosciences
COGT
186 hedge funds and large institutions have $800M invested in Cogent Biosciences in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 66 increasing their positions, 52 reducing their positions, and 20 closing their positions.
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
27% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 52
7.06% more ownership
Funds ownership: 110.19% → 117.25% (+7.1%)
6% more funds holding
Funds holding: 176 → 186 (+10)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
16% less capital invested
Capital invested by funds: $949M → $800M (-$150M)
75% less call options, than puts
Call options by funds: $355K | Put options by funds: $1.42M
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$31.7M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$23.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.7M |
| 4 |
CC
Commodore Capital
New York
|
+$15.8M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.7M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$33.5M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$7.18M |
| 3 |
SFAM
Springhill Fund Asset Management
Hong Kong
|
-$4.07M |
| 4 |
Walleye Capital
New York
|
-$3.16M |
| 5 |
CM
Crestline Management
Fort Worth,
Texas
|
-$2.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RS
201
R Squared
Central,
Hong Kong
| – | -$7.1K | -910 | Closed |
|
|
PWMG
202
Private Wealth Management Group
Princeton,
New Jersey
| – | -$2.22K | -284 | Closed |
|
|
SAM
203
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$2.1K | -273 | Closed |
|
204
Bessemer Group
Woodbridge,
New Jersey
| – | -$917 | -117 | -65% |
|
|
AF
205
Allworth Financial
Folsom,
California
| – | -$271 | -33 | Closed |
|
COGT Hedge Fund Activity: Q1 2025 in Review
186 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2025, worth a combined $800M — down 16% from $949M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new COGT positions and 20 closed out — a net gain of 11 holders — while 66 added to existing stakes and 52 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $31.7M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $33.5M sold.
- 186 institutional investors held Cogent Biosciences (COGT) as of Q1 2025, up from 176 in Q4 2024.
- Funds reported $800M of Cogent Biosciences stock for Q1 2025, down 16% quarter-over-quarter.
- 31 funds opened new Cogent Biosciences positions in Q1 2025 and 20 closed out, a net change of +11 holders.
- The largest Cogent Biosciences buyer in Q1 2025 was Paradigm Biocapital Advisors, an estimated $31.7M added.
- The largest Cogent Biosciences seller in Q1 2025 was Adage Capital Partners, an estimated $33.5M sold.
Based on aggregated 13F filings for Q1 2025.